PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Item

http://www.wikidata.org/entity/Q39767744

Q39767744

about

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis.Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.PI3K inhibition to overcome endocrine resistance in breast cancer.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

P2860

Q33442144-D58BE2F1-AF01-4001-8907-637D6451917C Q33921084-E3CCE3AE-BBBE-440D-BA6A-F39C9697ABF9 Q38377393-BAD54F94-C00D-4031-91D4-C31B9936B5FE Q38648765-4A613F07-469A-4A54-BF58-D4D9DF80AE45 Q38661390-0FF35350-55FB-42AE-8732-1DFF0DB05828 Q38752902-A0B76251-CBF0-48E0-A9FE-A24008FB0681 Q38843575-6CA5AD50-28FE-4A9F-BE6A-7D9F7A8EF4A0 Q39023175-CD7DF8BF-2D01-44CC-96EA-5053C4E7B75E Q39421814-5D907BCE-B472-4C93-A1E2-CC40B1CD7754 Q41149668-3FB0FAD9-CFB1-42A8-A0B7-DE034CD58B85 Q47725954-BDC31C5E-145D-4E4D-90B6-D948441C22A1 Q47776273-7947E746-F669-44AC-9666-F090D8C9DBC2 Q50115014-B4911EA9-C25B-4F01-860B-7ABA2357D3DA Q50525106-31D281F7-51AD-4E3C-8E6B-6DA746278DCF Q52633197-C1C2F8D2-A763-4971-810A-185CD732F068 Q54187441-36BE15A7-619E-476A-87BF-CFEED2A8E610 Q55004879-9F4B2D74-7046-4ADB-A90E-75E6ADD59F5A Q55428234-66D1AD06-0EE4-45EE-8D77-DA237E3D576A Q55435506-D9815FC7-F21D-4704-9730-9103710EF98C Q57495764-2790A3B3-0F1C-4C7B-9DE2-7A3FED8D6253 Q58797604-142A4AFC-4453-401F-BFC6-DC8D6A788D83

P2860

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Item

http://www.wikidata.org/entity/Q39767744

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@en

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@nl

type

Item

label

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@en

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@nl

prefLabel

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@en

PIK3CA mutations are associate ...... ing lapatinib and trastuzumab.

@nl

P1476

PIK3CA mutations are associate ...... ting lapatinib and trastuzumab

@en

P2093

C Schem

http://www.w3.org/2001/XMLSchema#string

C Sotiriou

http://www.w3.org/2001/XMLSchema#string

E Holmes

http://www.w3.org/2001/XMLSchema#string

G von Minckwitz

http://www.w3.org/2001/XMLSchema#string

J Baselga

http://www.w3.org/2001/XMLSchema#string

M Piccart

http://www.w3.org/2001/XMLSchema#string

M Untch

http://www.w3.org/2001/XMLSchema#string

S Loibl

http://www.w3.org/2001/XMLSchema#string

V Nekljudova

http://www.w3.org/2001/XMLSchema#string

P2860

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

P304

1519-1525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDW197

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27177864

http://www.w3.org/2001/XMLSchema#string

P932

6279074

http://www.w3.org/2001/XMLSchema#string

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

about

P2860

P2860

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932